Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817-MedSci.cn

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Paz-Ares, LG; Ciuleanu, TE; Pluzanski, A; Lee, JS; Gainor, JF; Otterson, GA; Audigier-Valette, C; Ready, N; Schenker, M; Linardou, H; Caro, RB; Provencio, M; Zurawski, B; Lee, KH; Kim, SW; Caserta, C; Ramalingam, SS; Spigel, DR; Brahmer, JR; Reck, M; O'Byrne, KJ; Girard, N; Popat, S; Peters, S; Memaj, A; Nathan, F; Aanur, N; Borghaei, H

Paz-Ares, LG (通讯作者)，Univ Complutense Madrid, Hosp Univ 12 Octubre, Med Oncol Dept, Ave Cordoba SN, Madrid 28041, Spain.

Abstract

Introduction: We characterized the safety of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large patient population with metastatic NSCLC and e......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

科室

工具

服务